Document 0600
 DOCN  M9490600
 TI    Treatment of coccidioidomycosis with SCH 39304.
 DT    9411
 AU    Hostetler JS; Catanzaro A; Stevens DA; Graybill JR; Sharkey PK; Larsen
       RA; Tucker RM; al-Haidary AD; Rinaldi MG; Cloud GA; et al; Department of
       Medicine, Santa Clara Valley Medical Center, San; Jose, CA 95128-2699.
 SO    J Med Vet Mycol. 1994;32(2):105-14. Unique Identifier : AIDSLINE
       MED/94343183
 AB    A new oral triazole antifungal, SCH 39304, was administered to 54
       patients with progressive infections due to Coccidioides immitis from
       six collaborating centers. Patients were grouped according to site of
       infection including chronic pulmonary (25), bone/joint (17) and
       skin/soft tissue (12). The median age was 40 years; 83% were male, 52%
       white, 13% HIV-infected and 35% had failed previous therapy. The
       majority of patients were treated with either 100 mg or 200 mg day-1.
       One patient on renal dialysis received 300 mg day-1. Baseline
       abnormalities were reassessed for evidence of efficacy every 4 months
       and expressed in a standardized scoring system. Cumulative overall
       response rates at 4, 8 and 12 months were 7%, 36% and 66% respectively.
       Twelve month response rates by disease were 77% (pulmonary), 62%
       (skin/soft tissue) and 31% (bone/joint). Fifteen patients failed therapy
       although seven of these were still on treatment when the study was
       discontinued. Two failed due to toxicity. Possible symptoms or signs of
       toxicity occurred in 24 (44%) patients and were generally mild. SCH
       39304 is an effective and well tolerated therapy for progressive forms
       of coccidioidomycosis.
 DE    Administration, Oral  Adult  Aged  Aged, 80 and over  Antifungal
       Agents/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/  PHARMACOKINETICS
       Coccidioidomycosis/*DRUG THERAPY  Dermatomycoses/*DRUG THERAPY  Drug
       Administration Schedule  Female  Human  HIV
       Infections/COMPLICATIONS/DRUG THERAPY  Joint Diseases/*DRUG THERAPY
       Lung Diseases, Fungal/*DRUG THERAPY  Male  Middle Age  Support, Non-U.S.
       Gov't  Support, U.S. Gov't, Non-P.H.S.  Support, U.S. Gov't, P.H.S.
       Treatment Outcome  Triazoles/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/
       PHARMACOKINETICS  CLINICAL TRIAL  JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).